Type I Ifn Immunoprofiling In Covid-19 Patients
THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Trouillet-Assant S, Viel S, Gaymard A, Pons S, Richard JC, Perret M, Villard M, Brengel-Pesce K, Lina B, Mezidi M, Bitker L and Belot A
J Allergy Clin Immunol. 2020 Apr 29. pii: S0091-6749(20)30578-9
COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-α2 production with about 20% of critically-ill patients unable to produce IFN-α2, highlighting the immune response heterogeneity and opening avenues for targeted therapies.
Share this page